NUVB News and Press, Nuvation Bio Inc. Class A

2026-03-06 16:35:58 ET Nuvation Bio Inc. (NUVB) TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript

2026-03-03 15:57:55 ET On February 17, 2026, Knoll Capital Management disclosed a purchase of 473,591 shares of Nuvation Bio (NYSE:NUVB) , an estimated $2.93 million trade based on quarterly average pricing. According to a February 17, 2026 SEC filing , Knoll Capital Managem...

2026-03-03 02:38:32 ET More on Nuvation Bio Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript Nuvation Bio Inc. 2025 Q4 - Results - Earnings Call Presentation Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade) Seeking Alp...

2026-03-03 02:37:49 ET Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call March 2, 2026 4:30 PM EST Company Participants Robert DeVita David Hung - Founder, President, CEO & Chairman Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - CFO & Prin...

2026-03-03 00:49:51 ET Image source: The Motley Fool. Monday, March 2, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-03-02 16:12:02 ET More on Nuvation Bio Nuvation Bio: Why Ibtrozi's 6x Adoption Rate Changes The Thesis (Rating Upgrade) Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference ...

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PR Newswire Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second h...

Astrana Health Inc. (ASTH) is expected to report $0.15 for Q4 2025 Sealed Air Corporation (SEE) is expected to report $0.72 for Q4 2025 Surgery Partners Inc. (SGRY) is expected to report $0.27 for Q4 2025 Kuehne + Nagel International AG ADR (KHNGY) is expected to report $0.4 for Q4 20...

2026-02-23 08:41:24 ET This article is part of a series that provides an ongoing analysis of the changes made to David Abrams’ 13F portfolio on a quarterly basis. It is based on Abrams’ regulatory 13F Form filed on 02/13/2026. Please visit our Tracking David Abrams&#...

2026-02-20 13:14:21 ET Overview My last evaluation of Nuvation Bio ( NUVB ) was in August 2025. While I acknowledged IBTROZI’s appeal in ROS1+ NSCLC, relative to other TKIs like AUGTYRO and ROZLYTREK, I also noted that it’s a small market and competition—in ...